Combination products are therapeutic and diagnostic products that combine drugs, devices, and/
or biological products. According to the US Food and Drug Administration (FDA), "a combination
product is one composed of any combination of a drug and a device; a biological product and
a device; a drug and a biological product; or a drug, device and a biological product." Examples
include prefilled syringes, pen injectors, autoinjectors, inhalers, transdermal patches, drug-eluting
stents, and kits containing drug administration devices co-packaged with drugs and/or biological
products. This handbook provides the most up-to-date information on the development of combination
products, from the technology involved to successful delivery to market. The authors present
important and up-to-the-minute pre- and post-market reviews of combination product regulations,
guidance, considerations and best practices.
This handbook:
- Brings clarity of understanding for combination products guidance and regulations
- Reviews the current state-of-the-art considerations and best practices spanning the combination
product lifecycle, pre-market through post-market
- Reviews medical product classification and assignment issues faced by global regulatory
authorities and industry
The editor is a recognized international Combination Products and Medical Device expert with
over 35 years of industry experience and has an outstanding team of contributors. Endorsed by
AAMI - Association for the Advancement of Medical Instrumentation.
About the Author: Susan Neadle, MS, BS, FAAO is a recognized international Combination Products and Medical Device expert with over 35 years of industry experience. Networked, published, highly active in numerous industry groups and with links to a number of teaching institutions, Susan brings deep knowledge and genuine passion for sharing that knowledge with others. Susan's leadership, innovation, and best practices have been recognized with multiple awards, including the Johnson Medal, Johnson & Johnson's highest honor for excellence in Research & Development, and most recently, as a Finalist in TOPRA's 2021 Awards for Regulatory Affairs Excellence. She serves as Principal Consultant and President of Combination Products Consulting Services LLC, applying her extensive leadership, technical skills, and complex program management experience to provide international quality & compliance, regulatory, design excellence and executive advisory consulting services to the pharmaceutical, biotech and medical device industries. Among her significant industry affiliations and contributions, she serves as Chair of the ISPE Combination Products CoP, lead author on the ASTM International Combination Products Standard Committee, lead author on the AAMI Combination Products Steering Committee, active member in Combination Products Coalition, and serves as faculty at AAMI and at University of Maryland Baltimore County Campus College of Natural and Mathematical Sciences for Combination Products Curricula.
Susan retired from Johnson & Johnson, where her distinguished 26+ year-career included integral leadership roles in R&D, Quality Engineering, Design-to-Value, and Quality Systems Management, spanning pharmaceuticals/biotech, medical devices, and consumer health sectors, as well as strategic leadership at J&J corporate level. She served as Chair of J&J's Design Council, advancing world-class practices in product and process design and development to drive robust, customer-centric health care solutions across J&J. She also led J&J's cross-sector Combination Products Community of Practice. Among several achievements, Susan led the team that defined and implemented the globally integrated business model to meet Combination Products health authority regulations for Janssen, J&J's Pharmaceutical sector, and was awarded the Johnson Medal for excellence in Research and Development.
Susan also served as Executive Director and Head of Combination Products, Medical Devices, Digital Health & IVD Regulatory Affairs at Amgen, providing strategic leadership in global combination products/ device regulatory development and portfolio/project management from initial clinical investigation through registration and commercial lifecycle. She was as an advisor for internal regulatory policy priorities, health authority engagement and submissions approaches through strategic engagement and mentoring of colleagues for individual projects and portfolio. She led interactions with multiple global health authorities, and served as a catalyst for external consortium deliverables and strategic direction.
